Following the success of immune checkpoint blockers (ICBs) in different cancer types, a
large number of studies are currently investigating ICBs in patients with hepatocellular …

Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

According to the 2020 European Society for Medical Oncology (ESMO) guidelines, three
different therapeutic options are currently available as first-line treatment for patients with …

Abstract Background Immune checkpoints inhibitors (ICIs) have emerged as a treatment
option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab …

Background Advanced hepatocellular carcinoma (HCC) portends a poor prognosis;
however recent advances in first‐line and second‐line treatment options should yield …

Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …

Introduction: Immunotherapy is on the way to become the new standard of care for advanced
hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and …

Systemic therapy for hepatocellular carcinoma (HCC) has changed drastically since the
introduction of the molecular targeted agent sorafenib in 2007. Although sorafenib …

A couple of molecular-targeting medications, such as Lenvatinib, are available for the
treatment of hepatocellular carcinoma (HCC) in addition to Sorafenib in an advanced stage …